Abstract
Introduction The first-in-class BTK inhibitor ibrutinib has substantially changed the therapeutic landscape of chronic lymphocytic leukemia (CLL). The......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
